Glucotrack receives patent allowance for implantable CBGM platform

RUTHERFORD, N.J. – Glucotrack has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering its implantable continuous blood glucose monitoring platform. The application, titled “Methods and Systems for Continuously Monitoring the Glucose Level of a Patient,” expands intellectual property protection for the company’s fully implantable CBGM system as it advances toward commercialization. The filing follows three CBGM patents issued by the USPTO in late 2025 and further protects key technologies across Glucotrack’s sensor architecture, the company says. “This allowed application strengthens the protection around key elements of our CBGM, including novel sensor architectures designed to support long-term intravascular glucose monitoring,” said Paul V. Goode, PhD, president and CEO of Glucotrack. “Continuing to build our intellectual property is fundamental to our strategy as we advance the fully implantable system through clinical testing and toward commercialization.” The allowed claims cover implantable glucose monitoring systems that use an intravascular sensing lead coupled to an electronics assembly, including device architectures and methods designed to operate within the vasculature to support long-term glucose monitoring. They also cover electrode configurations, lead-based sensing structures and associated implantation methods for continuous glucose measurement. Glucotrack’s CBGM is a long-term implantable system with no wearable component, designed for up to three years of continuous blood glucose monitoring. The device measures glucose directly from blood, unlike traditional continuous glucose monitoring systems, which measure glucose from interstitial fluid. The CBGM is investigational and limited by federal law to investigational use.